Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12173145 | 0.83 | HSPB1 (0.47) | HSPB1KMT2AMEN1PABPC1GAA | |
| SCHEMBL25696241 | 0.83 | HSPB1 (0.47) | HSPB1KMT2AMEN1PABPC1GAA | |
| SCHEMBL27924585 | 0.83 | HSPB1 (0.47) | HSPB1KMT2AMEN1PABPC1GAA | |
| SCHEMBL12173136 | 0.83 | KMT2A (0.48) | HSPB1KMT2AMEN1PABPC1GAA | |
| SCHEMBL12173143 | 0.83 | HSPB1 (0.47) | HSPB1KMT2AMEN1PABPC1GAA | |
| SCHEMBL5004367 | 0.81 | KMT2A (0.51) | HSPB1KMT2AMEN1PABPC1GAA | |
| SCHEMBL14669487 | 0.81 | NPC1 (0.52) | HSPB1KMT2AMEN1PABPC1GAA | |
| SCHEMBL30980526 | 0.80 | HSPB1 (0.47) | HSPB1KMT2AMEN1PABPC1GAA | |
| SCHEMBL28074872 | 0.80 | HSPB1 (0.47) | HSPB1KMT2AMEN1PABPC1GAA | |
| SCHEMBL17672793 | 0.79 | HSPB1 (0.51) | HSPB1KMT2AMEN1PABPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
| EP-1802608-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040526-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | HSPB1 4439/4885KMT2A 2980/4885MEN1 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.